Segment, Geographic and Other Revenue Information - Narrative (Detail)	3 Months Ended
	Apr. 03, 2022 USD ($) operatingSegment	Dec. 31, 2021 USD ($)
Segment Reporting Information [Line Items]
Number of segments | operatingSegment	2
Total assets	$ 183,841,000,000	$ 181,476,000,000
Remaining performance obligation	30,000,000,000
Deferred revenues, current	3,108,000,000	3,067,000,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01
Segment Reporting Information [Line Items]
Remaining performance obligation	$ 18,000,000,000
Remaining performance obligation, period of recognition	9 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Segment Reporting Information [Line Items]
Remaining performance obligation	$ 12,000,000,000
Remaining performance obligation, period of recognition	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Segment Reporting Information [Line Items]
Remaining performance obligation	$ 300,000,000
Remaining performance obligation, period of recognition	1 year
U.S. Government [Member] | Comirnaty and Paxlovid [Member]
Segment Reporting Information [Line Items]
Deferred revenues	$ 3,300,000,000
Deferred revenues, current	3,000,000,000
Deferred revenues, noncurrent	258,000,000
U.S. Government [Member] | Comirnaty [Member]
Segment Reporting Information [Line Items]
Deferred revenues		3,300,000,000
Deferred revenues, current		3,000,000,000
Deferred revenues, noncurrent		249,000,000
Deferred revenue recognized	$ 1,600,000,000
U.S. Government [Member] | Paxlovid [Member]
Segment Reporting Information [Line Items]
Deferred revenues		$ 0
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | U.S. Government [Member] | Comirnaty and Paxlovid [Member]
Segment Reporting Information [Line Items]
Concentration risk	19.00%
Credit Concentration Risk [Member] | Trade Accounts Receivable [Member] | U.S. Government [Member] | Comirnaty and Paxlovid [Member]
Segment Reporting Information [Line Items]
Concentration risk	11.00%